SLU PP 332 Explained as a Research Compound and Not a Peptide

SLU-PP-332 is a lab-made molecule that people often search for as a peptide, but it is not one. This overview explains what SLU-PP-332 is, which receptors it targets, what the published mouse papers reported and what nobody knows yet about people. Terms such as slupp332 peptide and slu pp 332 peptide are common, so the label question comes first.

What SLU PP 332 Is and Why the Peptide Label Is Wrong

A peptide is a chain of amino acids. This compound is not built that way. It is a small synthetic organic molecule, the kind chemists make in a flask and test as a drug candidate, and it has no amino acid sequence at all. People still type slu-pp-332 peptide, slupp peptide or slupp332 peptide into search boxes, probably because the compound is sold and discussed next to real peptides. The wrong label matters. Small molecules and peptides differ in how they are made, how their purity is checked and how the body handles them. The earlier stops on this map explain how peptide chains are built and tested, and none of that carries over to a molecule like this one.

The name is a lab code. The letters SLU mark the research group that made it, and the number marks one compound in a chemical series. Searchers also write slu pp, slupp 332 and slu pp 332, and all of them mean the same compound. It entered the scientific literature in 2023, in a paper by Billon, Burris and colleagues that described it as a synthetic agonist of the estrogen-related receptors. The authors wrote that it had enough exposure in mice to serve as a tool for lab experiments. A tool compound exists to answer questions about a receptor. It is not a finished medicine.

The ERR Receptors Behind SLU PP 332

ERR stands for estrogen-related receptor. There are three, called alpha, beta and gamma, and each one sits inside the cell and switches genes on or off. Despite the name, they do not answer to estrogen. They are busy in tissues that burn a lot of fuel, such as muscle, and they help set how many mitochondria a cell makes and how well they run. The compound is described as a pan agonist, which means it activates all three, with the strongest pull on ERR alpha. The Signal line explains how a message usually starts at the cell surface. These receptors are a different case, because the molecule has to enter the cell to reach them.

Because the three receptors overlap, researchers use genetically modified mice to ask which one does the work. In the 2023 paper the authors reported that ERR alpha was critical for the gain in endurance. That is the main reason the literature calls the compound an exercise mimetic: it switches on a gene program that exercise also switches on. Read the word mimetic narrowly. A gene program is not a workout. Exercise also changes the heart, the bones, the blood vessels and mood, and no published work shows this molecule doing those things in a person. A related compound, SLU-PP-915, was described as orally active in a 2026 paper, so the series is still being explored in the lab.

SLU PP 332 Benefits in the Mouse Papers

The phrase slu-pp-332 benefits needs a careful reading, because every reported benefit comes from cells or mice. The 2023 paper in ACS Chemical Biology reported that the compound raised mitochondrial function and respiration in a muscle cell line. In mice it increased oxidative type IIa muscle fibers and improved exercise endurance. The 2024 paper in the Journal of Pharmacology and Experimental Therapeutics used mice made obese by diet and ob/ob mice. It reported higher whole body energy expenditure, more fat burning and less fat mass gain, along with better insulin sensitivity. Neither abstract gives a dose that can be carried to people, and this article does not either.

Three cautions apply. First, mouse results often fail to carry over, and obesity drugs have a long record of this. Second, much of the published work comes from the same group and its collaborators, and the 2023 paper discloses financial interests in a company linked to the research. Third, a search of ClinicalTrials.gov for the compound name returned no registered studies. Without safety trials, a benefit list is only a list of hypotheses for the next experiments, and a hypothesis is not a recommendation. Readers who meet a confident summary of benefits should ask which animal, which tissue and which measurement it came from, because that detail is usually missing from social posts and seller pages.

Doping Rules and the Missing Human Data

No human trial of this compound has been published, and the ClinicalTrials.gov search found none. That means nobody has measured how it behaves in a person, which amounts are tolerated, what the side effects are, how long it stays in the body or whether the mouse effects appear at all. Even the basic safety questions that every approved drug must answer, such as effects on the heart, liver and hormones, are open. Compounds sold as research chemicals skip that step, and the buyer carries all of the risk. The lack of data also means there is no basis for a human amount, so none is given here, and any figure on a seller page or forum has no trial behind it.

The compound has also drawn the attention of anti doping labs. Two 2026 papers, one in Drug Testing and Analysis and one in Rapid Communications in Mass Spectrometry, mapped how the molecule is broken down in vitro so that its use can be detected. The first states that the World Anti-Doping Agency prohibits exercise mimetics and metabolic modulators. Athletes should read the current Prohibited List wording for category S4 themselves, because the lists change each year. Anyone subject to drug testing should treat any use as a risk to their career, on top of the unknown health risk. Under anti doping rules in general, the athlete is responsible for what is in the body.

Conclusion

SLU-PP-332 is a small molecule that activates the three estrogen-related receptors, not a peptide. Mouse papers from 2023 and 2024 report better endurance, more fat burning and less weight gain, and no human trial exists. Treat any claim about slu-pp-332 benefits as a hypothesis, and expect anti doping rules to apply to athletes.